ArticlePacing and clinical electrophysiology : PACE2025
Trends and Outcomes of Anticoagulation for Post-Operative Atrial Fibrillation After Coronary Artery Bypass Graft.
Article in Pacing and clinical electrophysiology : PACE, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Triple Therapy With Rivaroxaban in Patients With Acute Myocardial Infarction and Prior Atrial Fibrillation.Pacing and clinical electrophysiology : PACE · 2026Article
- Perioperative Arrhythmias: Pathophysiology, Risk Stratification, Management, and Emerging Technologies-A Narrative Review Toward Personalised Care.Journal of personalized medicine · 2026Review
- Trends and Outcomes of Anticoagulation for Post-Operative Atrial Fibrillation After Coronary Artery Bypass Graft.Pacing and clinical electrophysiology : PACE · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe benefit of oral anticoagulation (OAC) in patients with new-onset postoperative atrial fibrillation (POAF) after coronary bypass grafting remains uncertain. The 2023 American Heart Association (AHA) and the American College of Cardiology (ACC) guidelines recommend 60 days of anticoagulation for POAF, whereas management was previously left to the physician's discretion. The aim of this study is to identify the most effective anticoagulant regimens for reducing stroke rates in POAF patients after coronary artery bypass grafting (CABG).
methodsUsing the Epic Cosmos database, we included all US patients who underwent CABG without concomitant aortic/mitral valve replacement (MVR) from 2017 to 2023. Primary outcomes include demographics of POAF/non-POAF patients and complication rates among patients without anticoagulation, on direct oral anticoagulation (DOAC), or on warfarin.
resultsOf the 147,546 patients studied, 7.6% (11,336) developed POAF. At 60 days, the use of OAC for POAF was associated with a decrease in all-cause mortality without any difference in thromboembolism rates. At 12 months, there was no difference between all-cause mortality and thromboembolism rates between the OAC and the no anticoagulation (NA) cohorts.
conclusionsThe benefit of long-term anticoagulation of POAF following CABG with warfarin or DOAC remains unclear, as there was no reduction in thromboembolic events with anticoagulation despite a reduction in all-cause mortality at 60 days. No significant reduction in thromboembolic events or all-cause mortality was exhibited at 1 year. Thus, the benefit of long-term anticoagulation of POAF following CABG with warfarin or DOAC remains unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.